Table 2.
First-line chemotherapy for advanced or recurrent STS (phase 3 trial, including uLMS).
| Regimen | Year | Patients (n) | LMS (n) | uLMS (n) | ORR (%) | mPFS (Months) | mOS (Months) |
|---|---|---|---|---|---|---|---|
| Dox vs. Dox + CPA [16] | 1985 | 104 | 38 | 38 | 19 vs. 19 | 5.1 vs. 4.9 | 11.6 vs. 10.9 |
| Dox + DTIC bolus vs. infusion [17] | 1991 | 240 | 105 | 27 | 17 vs. 17 | NA | NA |
| GD + placebo vs. GD + Bev [12] | 2015 | 107 | 107 | 107 | 31.5 vs. 35.8 | 6.2 vs. 4.2 | 26.9 vs. 23.3 |
| Dox vs. GD [13] | 2017 | 257 | 118 | 71 | 19 vs. 20 | 5.8 vs. 5.9 | 19.1 vs. 16.8 |
| Dox + placebo vs. Dox + olaratumab [14] | 2020 | 506 | 234 | 94 | 18.3 vs. 14.0 | 6.8 vs. 5.4 | 19.7 vs. 20.4 |
STS, soft tissue sarcoma; uLMS, uterine leiomyosarcoma; n, number; LMS, leiomyosarcoma; ORR, objective response rate; mPFS, median progression-free survival; mOS, median overall survival; NA, not available; Dox, doxorubicin; CPA, cyclophosphamide; DTIC, dacarbazine; GD, gemcitabine + docetaxel; Bev, bevacizumab.